Shifts in Urbanicity-Based Access to Radiotracers for Neuroendocrine Tumors
- 30 April 2026
- journal article
- Published by Elsevier in Journal of the American College of Radiology
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- 64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor–Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical TrialJournal of Nuclear Medicine, 2020
- Improving Contrast and Detectability: Imaging with [55Co]Co-DOTATATE in Comparison with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATEJournal of Nuclear Medicine, 2019
- Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine TumorsJournal of Nuclear Medicine, 2017
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 2017
- Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine TumorsJournal of Nuclear Medicine, 2016
- 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-AnalysisJournal of Nuclear Medicine, 2016
- Rural‐urban disparities in incidence and outcomes of neuroendocrine tumors: A population‐based analysis of 6271 casesCancer, 2015
- Geographic and Sociodemographic Disparities in PET Use by Medicare Beneficiaries With CancerJournal of the American College of Radiology, 2012
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993